NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis $0.45 +0.10 (+29.05%) As of 07/11/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vaxart Stock (NASDAQ:VXRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxart alerts:Sign Up Key Stats Today's Range$0.33▼$0.4750-Day Range$0.30▼$0.7052-Week Range$0.26▼$1.07Volume4.67 million shsAverage Volume2.66 million shsMarket Capitalization$102.24 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company Overview Vaxart, Inc. is a clinical‐stage biotechnology company focused on the development of orally administered recombinant vaccines delivered in tablet form. Utilizing its proprietary VAAST™ (Vaccine‐Assisted Antigen Presentation System Technology) platform, Vaxart aims to stimulate both mucosal and systemic immune responses without the need for injections. The company’s approach is designed to simplify distribution logistics, eliminate cold‐chain requirements, and improve patient compliance by offering needle‐free vaccination options. Vaxart’s pipeline includes oral vaccine candidates for respiratory and enteric diseases. Among its lead programs is an oral COVID‐19 vaccine candidate intended to bolster mucosal immunity at the point of viral entry. In addition, Vaxart is advancing oral formulations targeting influenza and norovirus, each intended to provide broad protection and ease of administration. The company has engaged in preclinical and clinical collaborations to assess immunogenicity, safety and potential for rapid scale‐up should regulatory approvals be obtained. Founded in 2010 and headquartered in South San Francisco, California, Vaxart leverages a multidisciplinary team with expertise in virology, immunology and pharmaceutical development. The company has established manufacturing partnerships to support tablet formulation and has explored global distribution channels to address unmet vaccine needs in both developed and emerging markets. Vaxart’s leadership team is led by Chief Executive Officer Andrei Floroiu, whose prior roles include senior finance positions at public biotechnology companies, and Chief Scientific Officer Dr. Rich Malley, who brings extensive experience in vaccine research and development.AI Generated. May Contain Errors. Read More Vaxart Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreVXRT MarketRank™: Vaxart scored higher than 68% of companies evaluated by MarketBeat, and ranked 270th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has received no research coverage in the past 90 days.Read more about Vaxart's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.39) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxart's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.37% of the float of Vaxart has been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaxart has recently decreased by 96.08%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.37% of the float of Vaxart has been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaxart has recently decreased by 96.08%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.06 News SentimentVaxart has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vaxart this week, compared to 2 articles on an average week.Search Interest8 people have searched for VXRT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions.Read more about Vaxart's insider trading history. Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Stock News HeadlinesVaxart (NASDAQ:VXRT) & Xenetic Biosciences (NASDAQ:XBIO) Head-To-Head ContrastJuly 12 at 2:07 AM | americanbankingnews.comOTC Markets Group Welcomes Vaxart, Inc. to OTCQXJuly 8, 2025 | financialpost.comFThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because there's a $15 fund tied directly to gold's surge that's still paying massive income… Up to 64% annually — with payouts every 30 days.July 12 at 2:00 AM | Investors Alley (Ad)Vaxart Announces Preliminary Results of Annual Meeting of StockholdersJune 13, 2025 | globenewswire.comVaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJune 11, 2025 | globenewswire.comVaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus TrialJune 10, 2025 | globenewswire.comVaxart Announces Adjournment of Annual Meeting of StockholdersJune 2, 2025 | globenewswire.comVaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025May 29, 2025 | globenewswire.comSee More Headlines VXRT Stock Analysis - Frequently Asked Questions How have VXRT shares performed this year? Vaxart's stock was trading at $0.6621 at the beginning of the year. Since then, VXRT shares have decreased by 32.4% and is now trading at $0.4478. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) announced its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The biotechnology company earned $20.88 million during the quarter, compared to analyst estimates of $2.85 million. Vaxart had a negative net margin of 122.63% and a negative trailing twelve-month return on equity of 91.89%. Read the conference call transcript. When did Vaxart's stock split? Vaxart's stock reverse split on the morning of Wednesday, February 14th 2018.The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA). Company Calendar Last Earnings5/13/2025Today7/12/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees120Year Founded2004Price Target and Rating Average Price Target for Vaxart$3.00 High Price Target$4.00 Low Price Target$2.00 Potential Upside/Downside+569.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.95 million Net Margins-122.63% Pretax Margin-121.98% Return on Equity-91.89% Return on Assets-38.40% Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual Sales$47.40 million Price / Sales2.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.72Miscellaneous Outstanding Shares228,310,000Free Float222,374,000Market Cap$102.24 million OptionableOptionable Beta1.14 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:VXRT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.